2型糖尿病における骨転移マーカーに対するGIP,GLP-1およびGLP-2の別々の効果と組み合わせ
Josefine V Hansen1, David S Mathiesen1, Mikkel B Christensen1,2,3
1Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
The Journal of clinical endocrinology and metabolism
|August 29, 2025
まとめ
2型糖尿病では,口服によるグルコース耐性検査は,静脈注入グルコースよりも骨の吸収を抑制します. 腸内ホルモンのグルコース依存性インスリントロプ型ポリペプチド (GIP),グルカゴン型ペプチド1 (GLP-1),およびGLP-2が共同でこの効果を媒介する.
科学分野:
- 内分泌学
- メタボリズム
- 骨の生物学
背景:
- 口服によるグルコース耐性検査 (OGTT) は,同糖血性静脈注射グルコース (IIGI) よりも急性骨再吸収抑制を示す.
- 食後の骨の周回における腸由来ホルモンの役割については,さらなる解明が必要である.
研究 の 目的:
- グルコース依存型インスリン型ポリペプチド (GIP),グルカゴン型ペプチド1 (GLP-1),グルカゴン型ペプチド2 (GLP-2) が食後の骨の周回に与える個々の効果と組み合わせた効果を調査する.
- 2型糖尿病患者の特定の腸内ホルモン注入で,OGTTとIIGIの骨転移反応を比較する.
主な方法:
- 2型糖尿病 (T2D) の10人の参加者を対象としたランダム化クロスオーバー研究.
- 参加者は6日間にわたってOGTTと5回のIIGIを受け,塩水,GIP,GLP-1,GLP-2,およびGIP+GLP-1+GLP-2を含む注射を受けた.
- I型コラーゲンのカーボキシ末端テロペプチド (β-CTX- I) と,骨形成のマーカーであるプロコラーゲンI型N末端プロペプチド (PINP) の血濃度を測定した.
主要な成果:
- OGTTはIIGIよりもβ-CTX-Iレベルを著しく抑制した.
- GIP + GLP- 1 + GLP- 2をIIGIで併用すると,OGTTで観察されたβ- CTX- I抑制を模倣した.
- GIP,GLP-1,またはGIP+GLP-1+GLP-2の併用投与ではPINPの有意な低下は認められなかったが,OGTTおよびGLP-2の投与ではPINPの低下が見られた.
結論:
- T2D患者における食後の骨再吸収抑制は,GIP,GLP- 1およびGLP- 2の添加作用によって媒介される.
- これらの腸内ホルモンは,グルコースを摂取した後の骨の循環を調節する上で重要な役割を果たします.
関連する概念動画
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K


